… ProQR Announces Conference Presentations for Axiomer® RNA … the Netherlands, April 30, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … in May. Presentation at the TIDES 2018 Conference ProQR will deliver a presentation on the Axiomer ® RNA …
… ProQR Receives Fast Track Designation from FDA for QR-421a … & CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … disease,” said Daniel de Boer, Chief Executive Officer of ProQR. “We are also looking forward to begin enrollment in …
… ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of … in Tübingen, Investigator in the ILLUMINATE trial. “ProQR’s RNA therapy for the p.Cys998X mutation showed the … Aniz Girach, Ophthalmologist and Chief Medical Officer of ProQR. “With the ongoing trials in LCA10 and Ushers syndrome …
… ProQR Announces Presentations and Investor & Analyst Event at … LEIDEN, the Netherlands, Oct. 24, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Questionnaire-Revised Respiratory Symptom Score, or CFQ-R RSS) compared to placebo. A supportive trend was observed …
… On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day LEIDEN, the Netherlands, Feb. … said Daniel A. de Boer, Chief Executive Officer of ProQR. “Together with our partners at the Leiden Bio Science … Sariette Witte Investor Relations T: +1 213 261 8891 ir@proqr.com …
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early 2025
Axiomer activity demonstrated across multiple preclinical in vitro
… ProQR Announces Results for the Fourth Quarter and Full Year … said Daniel A. de Boer, Chief Executive Officer of ProQR. “QR-110, our second development program targeting … for QR-313 is expected to start in 2018. ProQR’s inaugural R&D day provides key updates on drug pipeline: On March 14 th …
… ProQR Announces Results for the Fourth Quarter and Full Year … of 2017 and Business Update QR-110 for LCA 10 In April, ProQR’s QR-110 for Leber’s congenital amaurosis 10 (LCA 10) … Questionnaire-Revised Respiratory Symptom Score, or CFQ-R RSS) compared to placebo. A supportive trend was observed …
… ProQR Strengthens Leadership with Appointments of CFO and CMO … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … brings over 20 years of global leadership in translational R&D, spanning early discovery to late-stage clinical …
… ProQR Highlights New Platform Data from Presentation on … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … mice,” said Gerard Platenburg, Chief Scientific Officer of ProQR. “To date, we have generated robust in vitro and in …
